Form 4: MapLight CMO Erin Foff Executes Stock Sale

Chief Medical Officer Erin Pennock Foff sold 4,438 shares of MapLight Therapeutics common stock via a 10b5-1 trading plan.

Summary

• Erin Pennock Foff, Chief Medical Officer of MapLight Therapeutics, Inc., sold a total of 4,438 shares of voting common stock on May 7, 2026.
• The sales were executed in two tranches: 4,321 shares at a weighted average price of $28.52 and 117 shares at a weighted average price of $29.10.
• Following these transactions, the reporting person retains beneficial ownership of 346,059 shares of the issuer.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 29, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted through a pre-established 10b5-1 plan, which is a routine administrative action for corporate insiders.

Positives

• The sale was pre-planned under a Rule 10b5-1 trading plan, which typically indicates the transaction is for personal financial management rather than a reaction to non-public information.

Negatives

• The sale represents a reduction in the insider's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived negatively by the market as a signal of management's view on the company's near-term valuation.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider sales executed via 10b5-1 plans are standard practice for executives in the biotechnology sector to manage personal liquidity while maintaining compliance with securities laws.

Comparison to Industry Standards

• The use of a 10b5-1 plan is the industry standard for corporate officers to divest shares without triggering concerns regarding insider trading regulations.

Stakeholder Impact

• Minimal impact expected as the sale was pre-planned and represents a small fraction of the officer's total holdings.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

MapLight Therapeutics, MPLT, Insider Trading, Form 4, Chief Medical Officer, Rule 10b5-1